一个十年前的CNN在皮肤癌诊断方面优于前沿LLM
A 10-year-old CNN outperforms frontier LLMs for skin cancer diagnosis

原始链接: https://lynchlab.net/llm-skin-cancer

Dr Magnus Lynch 在200例经活检证实的皮肤病变上测试了两个前沿大语言模型和一个较老的微调卷积神经网络。两个大语言模型正确诊断了42%(分别为84例和85例,共200例),而卷积神经网络正确诊断了62%(125例,共200例)。卷积神经网络的第二选择也表现更好(173例 vs 134例和138例),并识别出更多黑色素瘤(13例 vs 8例和11例)。大语言模型显示诊断偏向:GPT-6 Astra 过度诊断基底细胞癌,而 Claude 过度诊断光化性角化病。在安全性方面,大语言模型很少放行安全病变(100例中的32例和22例),但几乎保留了所有不安全病变(97例和96例);卷积神经网络放行了更多安全病变(76例),但在预设阈值下放行了更多黑色素瘤(18例),尽管阈值匹配降低了这一数字。局限包括样本量小、活检的难例、可能的训练数据污染,以及卷积神经网络并非最先进的。当以患者身份询问时,两个大语言模型通常建议看医生。总体而言,小型专用卷积神经网络在皮肤病变诊断上优于前沿大语言模型。

一篇 Hacker News 帖子讨论了一篇文章:十年前的 CNN(在皮肤图像上微调的 Inception v3)在 200 个皮肤病变分类任务中击败了前沿 LLM。评论者普遍认为,专用模型在狭窄、高风险任务上优于通用 LLM,尤其在相关数据上训练时。一些人认为,LLM 更适合作为通用工具/框架,可帮助构建或路由到专用分类器。另一些人质疑这一比较:CNN 可能具有域内优势,测试集较小,且所有病变均经过活检,这使真实标签更复杂。更广泛的结论是:LLM 并非普遍最优;专用分类器在特定领域仍很有价值,而 LLM 在编码、编排和低风险自动化方面表现突出。
相关文章

原文

I am a dermatologist. I tested the ability of GPT-6 Astra and Claude Fable 5.1 to diagnosis skin cancer and found that they were less accurate than I expected. I compared to a 10-year old CNN and to my surprise found that this was superior.

This is a melanoma.

Figure 1. Invasive melanoma on the ear, under 0.8 mm thick. Both LLMs called it a seborrhoeic keratosis and said it could be discharged. The CNN called it a melanoma. Clinical photograph on the left, dermoscopic image on the right. Images: MILK10k, MILK study team, CC BY-NC.

I showed these two images - a clinical photograph and a dermoscopic (skin microscope) image - to GPT-6 Astra and Claude Fable 5.1, two of the most capable AI models available in October 2026. Both said it was a seborrhoeic keratosis, a harmless warty growth, and that the patient could be discharged. I then showed them to fine-tuned version of Inception v3, a convolutional neural network (CNN) first published by Google in 2015 and fine-tuned here on public dermatology images. The CNN got the right answer based on the dermoscopy view.

It was one of 200 biopsy-proven lesions I gave to all three. The CNN named the right diagnosis (out of 6 possiblities) for 125 of them (62%). The two frontier LLMs named it for 84 and 85 (42%). A ten-year-old network, fine-tuned for about twenty minutes, beat both of them at recognising skin cancer.

The test

The lesions come from MILK10k, a public dataset released through the International Skin Imaging Collaboration in 2025, in which each lesion is photographed twice: a clinical close-up and a dermoscopic image taken through the illuminated magnifying lens dermatologists use. I drew 200 lesions at random, all confirmed by histopathology:

  • 100 that should not be discharged: 30 melanomas, 25 basal cell carcinomas, 25 squamous cell carcinomas (including Bowen’s disease) and 20 actinic keratoses.
  • 100 that are safe to discharge: 50 benign naevi (moles) and 50 seborrhoeic keratoses.

Every lesion was biopsied, including the benign ones, so these are harder to diagnose: a mole that somebody decided to cut out is one that worried a clinician.

Basal cell carcinoma on the trunk of a 75-year-old man. All three models answered correctly.

Invasive melanoma under 0.8 mm thick, with very little pigment. GPT-6 Astra called it a basal cell carcinoma with 95% confidence. Claude Fable 5.1 and the CNN called it a melanoma.

Seborrhoeic keratosis on the leg. Both LLMs called it an actinic keratosis and the CNN a squamous cell carcinoma: all three were wrong, though all three would have kept it rather than discharge it.

Figure 2. Three more of the 200 test lesions. Clinical photograph on the left, dermoscopic image on the right. Images: MILK10k, MILK study team, CC BY-NC.

The LLMs were given both images and nothing else, and asked, as a clinician might use them, for the most likely of the six diagnoses (or “unsure”), a confidence, a second choice, and whether the lesion could be safely discharged with no treatment, biopsy or follow-up. Both models got the same prompt at default settings, and neither refused a case.

The CNN is deliberately not state of the art. I used Inception v3 pretrained on everyday photographs and then fine-tuned all layers on 68,011 dermoscopic and clinical images from the ISIC Archive on a single H100 GPU. These 200 test lesions, and every other photograph of the same lesion or patient, were removed from its data (including the validation set) before training, so it had never seen them, and they were not used to choose the model or set its threshold. It scored both images of each lesion, combined them with most of the weight on the dermoscopic image, and chose from the same six diagnoses.

You can try the CNN yourself. Remarkably the model is small enough to run entirely in a phone browser using WebGPU. Nothing is uploaded, and its random sample button draws from these same 200 lesions.

Diagnosis: 62% against 42%

GPT-6 AstraClaude Fable 5.1Inception v3All 200 lesionsGPT-6 Astra - All 200 lesions: 84 of 200 (42%)84/200GPT-6 Astra - All 200 lesions: 84 of 200 (42%)Claude Fable 5.1 - All 200 lesions: 85 of 200 (42%)85/200Claude Fable 5.1 - All 200 lesions: 85 of 200 (42%)Inception v3 - All 200 lesions: 125 of 200 (62%)125/200Inception v3 - All 200 lesions: 125 of 200 (62%)By true diagnosisMelanomaGPT-6 Astra - Melanoma: 8 of 30 (27%)8/30GPT-6 Astra - Melanoma: 8 of 30 (27%)Claude Fable 5.1 - Melanoma: 11 of 30 (37%)11/30Claude Fable 5.1 - Melanoma: 11 of 30 (37%)Inception v3 - Melanoma: 13 of 30 (43%)13/30Inception v3 - Melanoma: 13 of 30 (43%)BCCGPT-6 Astra - BCC: 25 of 25 (100%)25/25GPT-6 Astra - BCC: 25 of 25 (100%)Claude Fable 5.1 - BCC: 18 of 25 (72%)18/25Claude Fable 5.1 - BCC: 18 of 25 (72%)Inception v3 - BCC: 24 of 25 (96%)24/25Inception v3 - BCC: 24 of 25 (96%)SCCGPT-6 Astra - SCC: 12 of 25 (48%)12/25GPT-6 Astra - SCC: 12 of 25 (48%)Claude Fable 5.1 - SCC: 5 of 25 (20%)5/25Claude Fable 5.1 - SCC: 5 of 25 (20%)Inception v3 - SCC: 16 of 25 (64%)16/25Inception v3 - SCC: 16 of 25 (64%)Actinic keratosisGPT-6 Astra - Actinic keratosis: 10 of 20 (50%)10/20GPT-6 Astra - Actinic keratosis: 10 of 20 (50%)Claude Fable 5.1 - Actinic keratosis: 12 of 20 (60%)12/20Claude Fable 5.1 - Actinic keratosis: 12 of 20 (60%)Inception v3 - Actinic keratosis: 9 of 20 (45%)9/20Inception v3 - Actinic keratosis: 9 of 20 (45%)NaevusGPT-6 Astra - Naevus: 16 of 50 (32%)16/50GPT-6 Astra - Naevus: 16 of 50 (32%)Claude Fable 5.1 - Naevus: 33 of 50 (66%)33/50Claude Fable 5.1 - Naevus: 33 of 50 (66%)Inception v3 - Naevus: 37 of 50 (74%)37/50Inception v3 - Naevus: 37 of 50 (74%)Seb. keratosisGPT-6 Astra - Seb. keratosis: 13 of 50 (26%)13/50GPT-6 Astra - Seb. keratosis: 13 of 50 (26%)Claude Fable 5.1 - Seb. keratosis: 6 of 50 (12%)6/50Claude Fable 5.1 - Seb. keratosis: 6 of 50 (12%)Inception v3 - Seb. keratosis: 26 of 50 (52%)26/50Inception v3 - Seb. keratosis: 26 of 50 (52%)0%25%50%75%100%
Figure 3. Correct first-choice diagnosis for the two LLMs and the CNN, which chose from the same six diagnoses. Labels show correct answers out of the number of lesions with that histology.

The CNN was right more often overall and on most diagnoses. Allowing a second choice, it reached 173 of 200 against 134 and 138. It named 13 of the 30 melanomas against 8 and 11. The biggest gap was on the harmless lesions: it recognised 37 of 50 moles and 26 of 50 seborrhoeic keratoses, against 16 and 13 for GPT-6 Astra and 33 and 6 for Claude Fable 5.1. It was one short of GPT-6 Astra on basal cell carcinoma and behind both LLMs on actinic keratosis.

The models also failed differently. Each LLM had a favourite answer: GPT-6 Astra called 75 lesions basal cell carcinoma when 25 were, including 14 of the 30 melanomas, and Claude Fable 5.1 called 53 lesions actinic keratosis when 20 were. The CNN’s errors on melanoma went the other way: of the 17 it got wrong, it called 8 a naevus and 6 a seborrhoeic keratosis.

The results in one table

GPT-6 Astra Claude Fable 5.1 CNN (Inception v3)
Correct diagnosis (of 200) 84 (42%) 85 (42%) 125 (62%)
Correct in first or second choice 134 138 173
Melanoma as first choice (of 30) 8 11 13
Unsafe lesions kept (of 100) 97 96 77 at its preset threshold; 98 or 99 when matched
Safe lesions discharged (of 100) 32 22 76 at its preset threshold
Melanomas discharged (of 30) 3 4 18 at its preset threshold; 2 or 1 when matched

Caveats

  • Small numbers. Two hundred lesions are enough to show the pattern but not to rank close results, and 30 melanomas give wide uncertainty on the figure that matters most. Each LLM case was run once; answers vary between runs.
  • Hard cases. Every lesion was biopsied. On ordinary images from the archive the CNN separated lesions that should and should not be discharged far better (area under the ROC curve 0.96, against 0.86 here).
  • Contamination. MILK10k has been public since 2025, so the LLMs could have seen it in training; if anything that would have helped them. The CNN certainly had not.
  • Not state of the art. Inception v3 is a baseline. State of the art skin cancer diagnosis AI uses ensembles of images transformers trained on more data, and the regulated products built on them perform considerably better.

Asked as a patient

Asked as a patient instead, with the clinical photograph alone and the question “do I need to see a doctor?”, both LLMs advised seeing a doctor in almost every case, harmless lesions included: for 99 and 98 of a further 100 biopsy-proven melanomas.

Conclusion

A small, old, specialised network using an outdated architecture recognises skin lesions far better than two frontier LLMs.

Run it yourself

The cases, prompts, every LLM reply and the scoring code are in one download, and the CNN is here.

I designed the test and made the clinical rulings. The analysis and the first drafts were produced with Claude Code, Anthropic’s coding tool, which runs on a Claude model; one of the two LLMs tested is also Anthropic’s. Scoring was done by script against the histology.

Images are from the MILK10k dataset (MILK study team, International Skin Imaging Collaboration), used under a CC BY-NC licence.

Dr Magnus Lynch is a Consultant Dermatologist and Mohs Surgeon at Guy's Hospital and Honorary Reader (equivalent of Associate Professor) at King's College London. His clinical work covers skin cancer, Mohs and facial reconstructive surgery, and lasers; his research covers the cell biology of skin cancers and scars and the use of AI in dermatology. Full profile.

联系我们 contact @ memedata.com